The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.

At a sometimes-contentious U.S. Senate hearing, the Health and Human Services secretary was evasive on the rationale behind ...

Sanofi expects to add “a significant number of high-paying jobs” in the U.S. with $20 billion investment through 2030.

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

It's another wild twist in the story of Galapagos, a company that has been around for more than 25 years but has yet to get a ...